XORTX Therapeutics Inc.
$2.07
+0.0050 (0.24%)
Join the XORTX Therapeutics Inc. Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow XORTX Therapeutics Inc. as new developments unfold.
Company Overview
XORTX Therapeutics is a Pharmaceutical company with late stage clinical therapies for gout and progressive kidney disease. The company’s lead asset, XORLO™, is being advanced for allopurinol-intolerant gout with the company preparing for commercialization and guiding to an NDA filing in 2026. These key steps position the company for future revenue generation. XORTX’s second late stage clinical program XRx-008 for autosomal dominant polycystic kidney disease (ADPKD) is poised for a registration-enabling study and XORTX maintains additional cardiorenal programs (XRx-101; XRx-225). In October 2025, XORTX expanded its kidney disease portfolio with the planned acquisition of VB4-P5, a novel anti-fibrotic small-molecule program from Vectus Biosystems. The program, supported by robust preclinical evidence and global IP, targets both rare and prevalent forms of progressive kidney disease. XORTX is led by an experienced management team and board with a track record of prior value-creating transactions.
Value Proposition
With multiple catalysts ahead, including pK clinical readouts, regulatory submissions, and strategic partnering opportunities, XORTX offers asymmetric upside potential. Reflecting this, Alliance Global Partners (AGP) issued a Buy rating with a $14 price target, underscoring Wall Street’s recognition of the company’s differentiated platform, near-term milestones, and large addressable market. For investors seeking exposure to high-impact pharmaceutical development with a clear path to commercialization and significant market opportunity, XORTX stands out as a timely and attractive choice.
It's lead drug candidate targeting gout is clinically de-risked and will be submitted to the FDA for near-term approval into a large well-established market where there is a significant unmet need. The FDA 505(b)(2) pathway offers reduced development risk, lower cost, and shorter timelines to market. With an NDA filing targeted in the next 12 months, XORTX is positioned to tap into an estimated billion-dollar U.S. market and $700M global peak sales potential.
The Company’s value proposition was further strengthened by the acquisition of the VB4-P5 renal anti-fibrotic program in October 2025 (pending ASX approval). This patent-protected small-molecule therapy has demonstrated compelling preclinical activity in models of kidney fibrosis — a central driver of progression in chronic kidney disease, ADPKD, and numerous rare renal disorders. With no approved anti-fibrotic therapies and a global CKD population exceeding 800 million individuals, VB4-P5 provides XORTX with a high-value, scalable opportunity that complements its late-stage programs and broadens its position as an emerging leader in the treatment of progressive kidney disease.
Investor Presentation
Investment Highlights
Late-stage lead program targeting significant unmet need in gout
- XORLO™ is a proprietary oral oxypurinol formulation designed for improved bioavailability in patients intolerant to allopurinol.
- NDA filing targeted for 2026 via FDA’s 505(b)(2) pathway; Type B meeting completed with regulatory clarity on approval steps.
- Addresses an estimated $700M annual U.S. market opportunity.
Large market potential with de-risked clinical profile
- Safe and effective in over 750 patients based on prior clinical data.
- Peak sales potential estimated at $700M for marketed allopurinol alternative.
- Commercialization planning underway, including pricing, reimbursement, and branding strategy development.
Multiple near-term catalysts
- IND submission (H2 2025) incorporating novel formulation, pharmacology, and clinical data.
- PK study results (XRX-OXY-102) expected H2 2025 to support population-based modeling for FDA/EMA filings.
- Completion of CMC validation and initiation of stability studies in 2025/2026 to support commercial readiness.
Expanding pipeline in kidney and cardiorenal diseases
- XRx-008 for autosomal dominant polycystic kidney disease (ADPKD) to enter registration trials, targeting >$5B market with orphan designation and potential accelerated approval.
- XRx-101 in development for acute kidney injury and organ injury associated with viral infections.
- Preclinical XRx-225 program targeting type 2 diabetic nephropathy.
- Acquisition of VB4-P5, a novel renal anti-fibrotic small molecule from Vectus Biosystems; expected to enter IND-enabling development following completion of acquisition; adds third renal therapeutic pillar alongside ADPKD and AKI programs.
Experienced leadership and proven track record
- Management and board members with successful prior exits, including Cynapsus Therapeutics ($624M) and Trillium Therapeutics ($2.2B).
- Key executives with deep regulatory, commercial, and partnering experience in nephrology and specialty pharma.
Buy rating with $14 price target from AGP
Sign Up For XRTX Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
XORTX (XRTX) is a client of RedChip Companies. XRTX agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in July 2025, for six month of investor awareness services. XRTX also agreed to pay RedChip a $67,500 fee for a 10-day national TV ad campaign aired weekdays in August 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.